专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019094607A2 IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019094607A2
公开(公告)日：2019-05-16
申请号：PCT/US2018/059849
申请日：2018-11-08
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PRINCIOTTA, Michael F. , CODER, Brandon , BALLI, David
摘要： Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such peptides, recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

2. 发明申请

WO2016126876A3 LISTERIA-BASED ADJUVANTS 审中-公开
标题翻译：李斯特菌为基础的佐剂
公开(公告)号：WO2016126876A3
公开(公告)日：2016-10-27
申请号：PCT/US2016016452
申请日：2016-02-03
申请人： ADVAXIS INC
发明人： PETIT ROBERT
IPC分类号： A61K39/39 , A61K35/74 , A61K39/02 , A61K48/00 , C07K14/195 , C12N9/10 , C12N9/16 , C12N9/88 , C12N15/74
CPC分类号： A61K35/74 , A61K39/001 , A61K39/0208 , A61K39/39 , A61K48/00 , A61K2039/522 , A61K2039/577 , A61K2039/585 , C07K14/195 , C07K14/335
摘要： This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
摘要翻译：本公开提供了用于使用单核细胞增生利斯特氏菌作为佐剂以增强受试者的免疫应答的方法和组合物。在某些情况下，本公开的方法可用于接受移植物的受试者。

3. 发明申请

WO2016154412A2 COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA BASED VACCINE FOR TREATING PANCREATIC CANCER 审中-公开
标题翻译： PD-1拮抗剂和基于LISTERIA的疫苗的组合用于治疗胰腺癌
公开(公告)号：WO2016154412A2
公开(公告)日：2016-09-29
申请号：PCT/US2016/023969
申请日：2016-03-24
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , ADVAXIS, INC.
发明人： BEATTY, Gregory L. , KNOBLOCK, Dawson , PETIT, Robert , PRINCIOTTA, Michael F. , WALLECHA, Anu
IPC分类号： A61K39/12 , A61K39/395 , A61K48/00 , A61P35/00
CPC分类号： A61K39/12 , A61K39/00 , A61K39/395 , A61K48/00 , A61K2039/55544 , A61K2039/585
摘要： The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the treatment of pancreatic cancer using an antagonist of a Programmed Death 1 protein (PD-1) in combination with a live attenuated recombinant Listeria strain comprising a fusion protein of a PEST sequence-containing polypeptide fused to a tumor-associated antigen.
摘要翻译：本发明涉及可用于治疗癌症的组合疗法。特别地，本发明涉及使用程序性死亡1蛋白（PD-1）的拮抗剂与活的减毒重组利斯特氏菌菌株联合治疗胰腺癌，其包含与肿瘤融合的含有PEST序列的多肽的融合蛋白相关抗原。

4. 发明申请

WO2016126876A2 LISTERIA-BASED ADJUVANTS 审中-公开
标题翻译：基于LISTERIA的ADJUVANTS
公开(公告)号：WO2016126876A2
公开(公告)日：2016-08-11
申请号：PCT/US2016/016452
申请日：2016-02-03
申请人： ADVAXIS, INC.
发明人： PETIT, Robert
IPC分类号： A61K39/39 , A61K39/02 , A61K35/74 , A61K48/00 , C12N15/74 , C12N9/10 , C12N9/16 , C12N9/88 , C07K14/195
CPC分类号： A61K35/74 , A61K39/001 , A61K39/0208 , A61K39/39 , A61K2039/522 , A61K2039/577 , A61K2039/585 , C07K14/195 , C07K14/335
摘要： This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
摘要翻译：本公开提供了使用单核细胞增多性李斯特菌素作为佐剂以增强受试者的免疫应答的方法和组合物。在某些情况下，本公开的方法可用于接受移植的受试者。

5. 发明申请

WO2019094607A3 IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019094607A3
公开(公告)日：2019-05-16
申请号：PCT/US2018/059849
申请日：2018-11-08
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PRINCIOTTA, Michael, F. , CODER, Brandon , BALLI, David
IPC分类号： C07K7/06 , C12N15/74 , A61K39/00 , A61K39/39 , A61P35/00
摘要： Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or Listeria strains comprising such peptides, fusion polypeptides, or nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such peptides, fusion polypeptides, nucleic acids, and recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such peptides, fusion polypeptides, nucleic acids, or recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such peptides, recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

6. 发明申请

WO2018129306A1 RECOMBINANT LISTERIA VACCINE STRAINS AND METHODS OF USING THE SAME IN CANCER IMMUNOTHERAPY 审中-公开
公开(公告)号：WO2018129306A1
公开(公告)日：2018-07-12
申请号：PCT/US2018/012570
申请日：2018-01-05
申请人： ADVAXIS, INC.
发明人： PETIT, Robert
IPC分类号： C12N15/74 , C07K14/005 , C07K14/195 , A61K39/02 , A61K39/00 , A61P35/00
CPC分类号： A61P35/00 , A61K39/00 , A61K39/02 , A61K39/12 , A61K2039/522 , A61K2039/523 , A61K2039/585 , A61K2039/6068 , A61K2039/86 , C07K14/195 , C12N2710/20034
摘要： Provided herein are recombinant fusion polypeptides comprising an HPV16 antigenic peptide and an HPV18 antigenic peptide, wherein the HPV16 antigenic peptide and the HPV18 antigenic peptide are operably linked in tandem (e.g., fused to a PEST- containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

7. 发明申请

WO2018085854A1 COMBINATION OF LISTERIA-BASED VACCINE WITH ANTI-CTLA-4 OR ANTI-CD137 ANTIBODIES 审中-公开
标题翻译：基于李斯特菌的疫苗与抗CTLA-4或抗CD137抗体的组合
公开(公告)号：WO2018085854A1
公开(公告)日：2018-05-11
申请号：PCT/US2017/060444
申请日：2017-11-07
申请人： ADVAXIS, INC.
发明人： HAYES, Sandra M. , KOSOFF, Rachelle , ZOU, Jun
IPC分类号： A61K39/12 , A61K39/39 , C07K14/195 , C07K16/28 , C12N15/74 , A61K39/00
摘要： The subject matter described herein is directed to methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen in combination with one or more other therapeutic agents to treat a tumor or metastatic cancer.
摘要翻译：本文所述的主题涉及治疗，防止和诱导针对人乳头瘤病毒相关肿瘤或癌症的免疫应答的方法，所述方法包括向受试者施用重组

8. 发明申请

WO2017132547A1 PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF 审中-公开
标题翻译：个性化递送基于传播的免疫疗法及其应用
公开(公告)号：WO2017132547A1
公开(公告)日：2017-08-03
申请号：PCT/US2017/015403
申请日：2017-01-27
申请人： ADVAXIS, INC.
发明人： PETIT, Robert , PERRY, Kyle , PRINCIOTTA, Michael F.
IPC分类号： C12N15/74 , C12N15/66 , C07K5/10 , C07K14/705 , A61K35/74 , A61K39/00 , A61K48/00
CPC分类号： A61K35/74 , A01K2267/0331 , A61K38/1709 , A61K39/0011 , A61K47/64 , A61K47/646 , A61K2039/522 , A61K2039/523 , A61K2039/6068 , C07K5/10 , C07K14/47 , C07K14/705 , C07K19/00
摘要： Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing frameshift-mutation-derived peptides associated with one or more neo-epitopes encoded by nucleic acid sequences comprising at least one frameshift mutation, wherein the frameshift mutation is specific to a subject's cancer or unhealthy tissue. A delivery vector of this disclosure includes bacterial vectors; or viral vectors, or peptide vaccine vectors; or DNA vaccine vectors including Listeria bacterial vectors comprising one or more fusion proteins comprising one or more frameshift-mutation-derived peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. Disclosed are also methods of using these compositions for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection in the subject.
摘要翻译：本文公开了用于患有疾病或病症的受试者的个体化免疫治疗组合物，包括治疗性疫苗递送载体及其制备方法，所述方法包括表达移码突变衍生肽与基因表达构建体相关的基因表达构建体，由包含至少一个移码突变的核酸序列编码的更多新表位，其中移码突变对个体的癌症或不健康组织特异。本公开的递送载体包括细菌载体; 或病毒载体或肽疫苗载体; 或DNA疫苗载体，包括含有一种或多种融合蛋白的李斯特菌细菌载体，所述融合蛋白包含一种或多种移码突变衍生的肽，所述肽包含存在于患有受试者的疾病的生物样品中存在的一种或多种新表位。还公开了使用这些组合物诱导抗疾病或病症（包括肿瘤或癌症）或受试者感染的免疫应答的方法。

9. 发明申请

WO2016011353A1 RECOMBINANT LISTERIA STRAIN EXPRESSING HETEROLOGOUS ANTIGEN FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
标题翻译：表达异源抗原融合蛋白的重组LISTERIA菌株及其使用方法
公开(公告)号：WO2016011353A1
公开(公告)日：2016-01-21
申请号：PCT/US2015/040911
申请日：2015-07-17
申请人： ADVAXIS, INC.
发明人： WALLECHA, Anu , PETIT, Robert , ELLENHORN, Joshua , DIAMOND, Don J.
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
CPC分类号： A61K39/0011 , A61K35/74 , A61K39/385 , A61K2039/522 , A61K2039/523 , A61K2039/572 , A61K2039/6037 , A61P35/00 , C07K14/195 , C07K14/4703 , C07K2319/40 , C07K2319/55 , C12N9/90 , C12N15/85 , C12N2800/107 , C12N2820/55 , C12Y501/01001
摘要： Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
摘要翻译：本文公开了编码与免疫原性多肽融合的肿瘤抗原的重组核酸和包含其的重组利斯特氏菌菌株，其制备方法，以及诱导免疫应答的方法，以及治疗，抑制或抑制癌症或肿瘤的方法，包括对其施用。

10. 发明申请

WO2015130810A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS 审中-公开
标题翻译：用于治疗HER2 / NEU超表达肿瘤的组合物和方法
公开(公告)号：WO2015130810A2
公开(公告)日：2015-09-03
申请号：PCT/US2015/017559
申请日：2015-02-25
申请人： ADVAXIS, INC. , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
发明人： SHAHABI, Vafa , WALLECHA, Anu , MACIAG, Paulo C. , PATERSON, Yvonne , MASON, Nicola , SEAVEY, Matthew
IPC分类号： A61K39/00
CPC分类号： A61K35/74 , A61K39/0011 , A61K2039/522 , A61K2039/523 , A61K2039/552 , A61K2039/57 , C07K2319/00
摘要： This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject.
摘要翻译：本发明提供用于治疗和接种针对HER2 / neu抗原表达的肿瘤并在受试者中诱导针对其的免疫应答的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式